Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight: Do Larger Series A Rounds Mean Less Successful Exits?

This article was originally published in The Pink Sheet Daily

Executive Summary

A five-year review of Series A financings finds no negative correlation between the size of an A round and the likelihood of an investor exit. Plus news on recent financings by Veracyte, Calithera Biosciences, Spark Therapeutics and Versant Ventures.

You may also be interested in...



CHOP Commits $50 Million To Gene Therapy Spin-Out Spark Therapeutics

Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.

With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders

The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.

Veracyte: How To Build A Molecular Cytology Company

Veracyte has launched a complex molecular diagnostic test in thyroid in record time and with impressive capital efficiency. It could be a model for high-value diagnostics, especially if the company can successfully adopt its approach in a broader market.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel